88 related articles for article (PubMed ID: 16005964)
1. Decreased expression of CCAAT/enhancer binding protein zeta (C/EBPzeta) in patients with different myeloid diseases.
Qian J; Chen Z; Lin J; Wang W; Cen J
Leuk Res; 2005 Dec; 29(12):1435-41. PubMed ID: 16005964
[TBL] [Abstract][Full Text] [Related]
2. Aberrant methylation of CCAAT/enhancer binding protein zeta promoter in acute myeloid leukemia.
Yao DM; Qian J; Lin J; Wang YL; Chen Q; Qian Z; Li Y; Wang CZ; Yang J
Leuk Res; 2011 Jul; 35(7):957-60. PubMed ID: 21106240
[TBL] [Abstract][Full Text] [Related]
3. Gene expression profiling of the bone marrow mononuclear cells from patients with myelodysplastic syndrome.
Qian J; Chen Z; Wang W; Cen J; Xue Y
Oncol Rep; 2005 Nov; 14(5):1189-97. PubMed ID: 16211284
[TBL] [Abstract][Full Text] [Related]
4. [Quantitative study on C/EBP zeta gene transcripts in patients with chronic myeloid leukemia using real-time quantitative PCR].
Qian J; Chen ZX; Lin J; Hu SY; Cen JN; Wang W
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2005 Dec; 22(6):628-31. PubMed ID: 16331558
[TBL] [Abstract][Full Text] [Related]
5. C/EBPzeta (CHOP/Gadd153) is a negative regulator of LPS-induced IL-6 expression in B cells.
Gao H; Schwartz RC
Mol Immunol; 2009 Dec; 47(2-3):390-7. PubMed ID: 19782405
[TBL] [Abstract][Full Text] [Related]
6. CEBPA polymorphisms and mutations in patients with acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma and non-Hodgkin's lymphoma.
Fuchs O; Provaznikova D; Kocova M; Kostecka A; Cvekova P; Neuwirtova R; Kobylka P; Cermak J; Brezinova J; Schwarz J; Markova J; Salaj P; Klamova H; Maaloufova J; Lemez P; Novakova L; Benesova K
Blood Cells Mol Dis; 2008; 40(3):401-5. PubMed ID: 18182175
[TBL] [Abstract][Full Text] [Related]
7. Expression dynamics of drug resistance genes, multidrug resistance 1 (MDR1) and lung resistance protein (LRP) during the evolution of overt leukemia in myelodysplastic syndromes.
Kurata M; Hasegawa M; Nakagawa Y; Abe S; Yamamoto K; Suzuki K; Kitagawa M
Exp Mol Pathol; 2006 Dec; 81(3):249-54. PubMed ID: 16566920
[TBL] [Abstract][Full Text] [Related]
8. Expression of type 1 insulin-like growth factor receptor in marrow nucleated cells in malignant hematological disorders: correlation with apoptosis.
Qi H; Xiao L; Lingyun W; Ying T; Yi-Zhi L; Shao-Xu Y; Quan P
Ann Hematol; 2006 Feb; 85(2):95-101. PubMed ID: 16328478
[TBL] [Abstract][Full Text] [Related]
9. Low expression of the putative tumour suppressor gene gravin in chronic myeloid leukaemia, myelodysplastic syndromes and acute myeloid leukaemia.
Boultwood J; Pellagatti A; Watkins F; Campbell LJ; Esoof N; Cross NC; Eagleton H; Littlewood TJ; Fidler C; Wainscoat JS
Br J Haematol; 2004 Aug; 126(4):508-11. PubMed ID: 15287943
[TBL] [Abstract][Full Text] [Related]
10. PU.1 and CEBPA expression in acute myeloid leukemia.
D'Alò F; Di Ruscio A; Guidi F; Fabiani E; Greco M; Rumi C; Hohaus S; Voso MT; Leone G
Leuk Res; 2008 Sep; 32(9):1448-53. PubMed ID: 18308386
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of the Doppel protein in acute myeloid leukaemias and myelodysplastic syndromes.
Travaglino E; Comincini S; Benatti C; Azzalin A; Nano R; Rosti V; Ferretti L; Invernizzi R
Br J Haematol; 2005 Mar; 128(6):877-84. PubMed ID: 15755294
[TBL] [Abstract][Full Text] [Related]
12. [Expression of the CDH13 gene and BCR/ABL fusion gene in chronic myeloid leukemia patients and their relationship].
Mu HJ; Xie P; Shen YF; Jiang YQ
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2009 Feb; 26(1):98-101. PubMed ID: 19199263
[TBL] [Abstract][Full Text] [Related]
13. Real-time PCR as a tool for quantitative analysis of PI-PLCbeta1 gene expression in myelodysplastic syndrome.
Follo MY; Bosi C; Finelli C; Fiume R; Faenza I; Ramazzotti G; Gaboardi GC; Manzoli L; Cocco L
Int J Mol Med; 2006 Aug; 18(2):267-71. PubMed ID: 16820933
[TBL] [Abstract][Full Text] [Related]
14. Growth factor-independent 1B gene (GFI1B) is overexpressed in erythropoietic and megakaryocytic malignancies and increases their proliferation rate.
Elmaagacli AH; Koldehoff M; Zakrzewski JL; Steckel NK; Ottinger H; Beelen DW
Br J Haematol; 2007 Jan; 136(2):212-9. PubMed ID: 17156408
[TBL] [Abstract][Full Text] [Related]
15. Detailed analysis of FLT3 expression levels in acute myeloid leukemia.
Kuchenbauer F; Kern W; Schoch C; Kohlmann A; Hiddemann W; Haferlach T; Schnittger S
Haematologica; 2005 Dec; 90(12):1617-25. PubMed ID: 16330434
[TBL] [Abstract][Full Text] [Related]
16. PRAME mRNA levels in cases with acute leukemia: clinical importance and future prospects.
Paydas S; Tanriverdi K; Yavuz S; Disel U; Baslamisli F; Burgut R
Am J Hematol; 2005 Aug; 79(4):257-61. PubMed ID: 16044453
[TBL] [Abstract][Full Text] [Related]
17. [Study of nucleophosmin (NPM) gene mutation in patients with acute myeloid leukemia and myelodysplastic syndromes].
Zhang Y; Zhang MR; Yang L; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2006 Jul; 27(7):470-3. PubMed ID: 17147251
[TBL] [Abstract][Full Text] [Related]
18. Telomerase activity in myelodysplastic syndromes.
Gürkan E; Tanriverdi K; Başlamişli F
Leuk Res; 2005 Oct; 29(10):1131-9. PubMed ID: 16111531
[TBL] [Abstract][Full Text] [Related]
19. Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia.
Pabst T; Eyholzer M; Haefliger S; Schardt J; Mueller BU
J Clin Oncol; 2008 Nov; 26(31):5088-93. PubMed ID: 18768433
[TBL] [Abstract][Full Text] [Related]
20. Assessment of growth and differentiation processes in myelodysplastic syndromes by PCR analysis of Galpha16 and 5'-lipoxygenase.
Pfeilstöcker M; Karlic H; Nösslinger T; Tüchler H; Lohninger A; Pittermann E
Ann Hematol; 2002 Nov; 81(11):632-40. PubMed ID: 12454701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
